- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Clovis Oncology is a biotechnology & medical research business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 413 staff and has a trailing 12-month revenue of around $133 million.
|Latest market close||$0.09|
|52-week range||$0.04 - $3.25|
|50-day moving average||$0.41|
|200-day moving average||$1.22|
|Wall St. target price||$2.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.08|
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.093 from 2023-02-22
|1 week (2023-03-17)||N/A|
|1 month (2023-02-24)||N/A|
|3 months (2022-12-28)||57.63%|
|6 months (2022-09-28)||-92.12%|
|1 year (2022-03-24)||N/A|
|2 years (2021-03-26)||-98.56%|
|3 years (2020-03-27)||7.13|
|5 years (2018-03-27)||53.67|
Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$133 million|
|Gross profit TTM||$115.3 million|
|Return on assets TTM||-30.18%|
|Return on equity TTM||0%|
|Market capitalisation||$11.8 million|
TTM: trailing 12 months
We're not expecting Clovis Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $0.0422 up to $3.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 0.2205. This would suggest that Clovis Oncology's shares are less volatile than average (for this exchange).
Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U. S. , the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.